Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS)

CUSIP: 87184Q206

Q2 2024 13F Holders as of 30 Jun 2024

Holder snapshot 7 signals
Share change
-532,680
Put/Call ratio
15%
SEC-reported price per share
$5.16
Number of holders
70
Value change
-$2,839,834
Number of buys
30
Open additional details 1 more signal available
Number of sells
27
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
27,196,692

Security key

87184Q206

Report period

Q2 2024

Institutions

70

Top holders

10

Ownership snapshot

Top reported holders of SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Bain Capital Life Science...
Disclosed value leader
Bain Capital Life Science...
Comparable rows
0/15
Latest evidence
31 Mar 2024
13F Highest disclosed value: $14,711,473 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Bain Capital Life Sciences Investors, LLC has the largest disclosed position value at $14.71M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Bain Capital Life Sciences Investors, LLC's linked filing trail.
Disclosed position value Top 5
Bain Capital Life Sciences Invest... $14.71M
Artal Group S.A. $13.4M
ADAGE CAPITAL PARTNERS GP, L.L.C. $11.08M
Samsara BioCapital, LLC $9.56M
Avidity Partners Management LP $8.95M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Bain Capital Life Sciences Investors, LLC
13F
Company
13F
—
denominator unverified
$14,711,473
2,749,808 shares
— 31 Mar 2024
Artal Group S.A.
13F
Company
13F
—
denominator unverified
$13,401,820
2,505,013 shares
— 31 Mar 2024
ADAGE CAPITAL PARTNERS GP, L.L.C.
13F
Company
13F
—
denominator unverified
$11,084,740
2,071,914 shares
— 31 Mar 2024
Samsara BioCapital, LLC
13F
Company
13F
—
denominator unverified
$9,557,384
1,786,427 shares
— 31 Mar 2024
Avidity Partners Management LP
13F
Company
13F
—
denominator unverified
$8,953,428
1,673,538 shares
— 31 Mar 2024
Point72 Asset Management, L.P.
13F
Company
13F
—
denominator unverified
$7,873,975
1,471,771 shares
— 31 Mar 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
70
Shares
20,382,905
Rows available
70
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2024 vs Q1 2024 Across Filers

Q1 2024 holders
74
Q2 2024 holders
70
Holder diff
-4
Investor Q1 2024 Shares Q2 2024 Shares Share Diff Share Chg % Q1 2024 value Q2 2024 value Value change Value Chg %
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .